HeartSciences Inc. (HSCS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
HeartSciences Inc. (HSCS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 ea029748101ex10-2.htm RESTRICTED STOCK UNITS NOTICE OF GRANT AND RESTRICTED STOCK UNITS AGREEMENT, DATED AS OF JULY 7, 2026, BETWEEN HEARTSCIENCES AND DANIELLE WATSON Exhibit 10.2 HEARTSCIENCES INC. 2023 Equity Incentive Plan RESTRICTED STOCK UNITS GRANT NOTICE HeartSci
How this was made
The 30-second read
Why it matters
Based on the provided excerpt, the main disclosed event is an RSU grant (25,000 units) to Danielle Watson with vesting tied to a closing date and quarterly tranches.
Market read
This is a routine equity-compensation and governance filing with no new operating or financial datapoints in the excerpt.
What to watch
Traders may want to check the full 8-K for the specific departure/election details and any employment agreement terms, which are not included in the excerpt.
Background
The SEC 8-K includes Item 5.02 (director/officer changes and compensatory arrangements) and Item 3.02 (unregistered sales of equity securities).
Ticker impact
HeartSciences filed an 8-K for director/officer changes and granted 25,000 RSUs to Danielle Watson under its 2023 Equity Incentive Plan.
Likely minimal immediate price impact; any move would be sentiment-driven rather than driven by new operating guidance.
The excerpt discloses RSU grant terms and vesting mechanics, but no new financial results, guidance, contracts, or regulatory/clinical catalysts.
Market effects
No clear sector read-across from an RSU grant and officer/director appointment disclosure.
None indicated.
None indicated.
Counterpoint
If the director/officer changes signal a strategic pivot, the market could re-rate the story, but the provided text does not include such specifics.
Key entities
- issuerHeartSciences Inc.
Subject of the SEC 8-K, including director/officer changes and equity compensation disclosures.
- officerDanielle Watson
Recipient of a restricted stock units grant (25,000 RSUs) under the 2023 Equity Incentive Plan.
